DIY drug administration on rise

Market research group Greystone Research Associates estimates that the global value of non-oral drug self-administration will exceed $130 billion in 2014. Greystone lists four major factors as propelling non-oral self-delivery: an increase in approved drugs that just don't work in oral form, added cost and strain on the healthcare system that comes with patient visits to caregivers for drug treatments, availability of patient-friendly delivery methods, and a desire by patients to avoid routine caregiver visits. This presents a market opportunity for developers of user-friendly devices and delivery systems, Greystone says. Release | Report highlights

Suggested Articles

Kala Pharma's Eysuvis on Tuesday became the first and only corticosteroid approved to treat short-term signs and symptoms of dry eye disease.

Xeris scored an FDA fast track designation for its diazepam formulation, delivered via autoinjector, to treat acute repetitive seizures.

Armed with microrobots and magnetic fields, Pursue scientists are looking to the future of targeted drug delivery, starting with the colon.